Product news

Share this article:

Roche announced that the European Commission (EC) has given its approval for the wider use of Avastin (bevacizumab) in patients suffering from metastatic colorectal cancer. The new broader label will now allow Avastin to be used in combination with any chemotherapy, including Roche's oral chemotherapy Xeloda (capecitabine), for first and later treatment lines in patients with metastatic colorectal cancer. 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.